Business
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
IP will be used to pursue further indications for HT-001 Cancer Therapeutic NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"IP will be used to pursue further indications for HT-001 Cancer Therapeutic\nNEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline.\n\n \n \n \n \n \n \n\n \nThese newly secured patents reflect Hoth's commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on enhancing therapeutic efficacy and broadening applications across various disease areas.\n\"Our expanding intellectual property portfolio supports Hoth's position as a leader in innovative drug development,\" said Robb Knie, CEO of Hoth Therapeutics. \"These provisional patent applications reinforce our proprietary approaches and our mission to deliver breakthrough therapies that improve patients' lives.\"\nHoth Therapeutics continues to invest in robust research and development strategies, ensuring the protection and growth of its proprietary technologies. The company remains dedicated to advancing its pipeline and delivering impactful healthcare solutions.\nAbout Hoth Therapeutics, Inc.\nHoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.\nForward-Looking Statement\nThis press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the abil...